ArticleFrontiers in pharmacology2026
10-HDA attenuates inflammatory responses in LPS-activated RAW264.7 cells
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation is implicated in the pathogenesis of various diseases, including cancer, diabetes, and diseases caused by bacterial infections. Macrophages, as key regulators of inflammatory responses, can polarize into distinct phenotypes such as pro-inflammatory M1 and anti-inflammatory M2 macrophages. Trans-10-hydroxy-2-decenoic acid (10-HDA), a bioactive component of royal jelly (RJ), exhibits potent anti-inflammatory properties; however, its influence on macrophage polarization remains poorly understood. Methods: 10-HDA was used to uncover the mechanisms for LPS-induced inflammatory response in RAW264.7 cells. CCK8 assay, ELISA assay, western blot analysis, real-time PCR, immunofluorescence assay were performed to evaluate the protective effects of 10-HDA. Results: Our findings demonstrated that 10-HDA treatment upregulated M2 macrophage markers, enhanced the secretion of anti-inflammatory cytokines, and modulated multiple signaling pathways. Mechanistically, 10-HDA exerted its anti-inflammatory effects by targeting the NUR77/NF-κB pathway, suppressing the expression of inducible nitric oxide synthase (iNOS) while promoting the anti-inflammatory marker CD206. Additionally, 10-HDA significantly inhibited the production of pro-inflammatory cytokines, including IL-6, IL-1β, and TNF-α. Furthermore, 10-HDA influenced mitochondrial metabolism, suggesting a protective role in maintaining mitochondrial function. Conclusion: These results indicate that 10-HDA promotes M2 macrophage polarization through the NUR77/NF-κB signaling pathway and by mitigating mitochondrial dysfunction, highlighting its potential role in modulating innate immunity and its potential application in anti-inflammatory therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.